Douglas Hägerström
YOU?
Author Swipe
View article: Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images
Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images Open
Developing and validating sensitive visual read algorithms for assessing Alzheimer disease-related tau in tau PET imaging is imperative, considering the implementation of the methodology in clinical practice and trials. Our aim was to comp…
View article: A prospective study evaluating the clinical utility of tau‐PET in the diagnostic work‐up of patients with cognitive symptoms
A prospective study evaluating the clinical utility of tau‐PET in the diagnostic work‐up of patients with cognitive symptoms Open
Background Determining the added value of tau‐PET in the diagnostic work‐up of patients with cognitive symptoms is of great importance before implementation of the method in clinical practice. We therefore aimed to prospectively study the …
View article: Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms Open
Importance It is important to determine the added clinical value for tau positron emission tomography (PET) in the diagnostic workup of patients with cognitive symptoms before widespread implementation in clinical practice. Objective To pr…
View article: Comparing <sup>18</sup> F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
Comparing <sup>18</sup> F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease Open
This study provides Class III evidence that CSF tau and 18F-AV-1451 PET have similar performance in identifying early AD, and that 18F-AV-1451 PET is superior to CSF tau in identifying mild to moderate AD.
View article: In vivo retention of <sup>18</sup> F-AV-1451 in corticobasal syndrome
In vivo retention of <sup>18</sup> F-AV-1451 in corticobasal syndrome Open
This study provides Class III evidence that 18F-AV-1451 PET distinguishes between CBS and AD or PSP.
View article: <sup>18</sup> F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
<sup>18</sup> F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease Open
To elucidate the relationship between cerebrospinal fluid ( CSF ) total‐tau (T‐tau) and phosphorylated tau (P‐tau) with the tau PET ligand 18 F‐ AV ‐1451 in Alzheimer's disease ( AD ), we examined 30 cognitively healthy elderly (15 with pr…
View article: [O1–06–06]: SPATIAL CORRESPONDENCE OF ALZHEIMER's DISEASE‐RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS
[O1–06–06]: SPATIAL CORRESPONDENCE OF ALZHEIMER's DISEASE‐RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS Open
Neuropathological studies have shown that typical tau pathology in Alzheimer's disease (AD) preferentially affects specific brain regions whereas others remain relatively spared. The distinct regional spread of tau pathology in AD may be a…
View article: [IC‐P‐195]: SPATIAL CORRESPONDENCE OF ALZHEIMER's DISEASE‐RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS
[IC‐P‐195]: SPATIAL CORRESPONDENCE OF ALZHEIMER's DISEASE‐RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS Open
Neuropathological studies have shown that typical tau pathology in Alzheimer's disease (AD) preferentially affects specific brain regions whereas others remain relatively spared. The distinct regional spread of tau pathology in AD may be a…
View article: Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks
Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks Open
Neuropathological studies have shown that the typical neurofibrillary pathology of hyperphosphorylated tau protein in Alzheimer's disease (AD) preferentially affects specific brain regions whereas others remain relatively spared. It has be…
View article: Modeling Strategies for Quantification of In Vivo <sup>18</sup>F-AV-1451 Binding in Patients with Tau Pathology
Modeling Strategies for Quantification of In Vivo <sup>18</sup>F-AV-1451 Binding in Patients with Tau Pathology Open
Aggregation of hyperphosphorylated tau is a major hallmark of many neurodegenerative diseases, including Alzheimer disease (AD). In vivo imaging with PET may offer important insights into pathophysiologic mechanisms, diagnosis, and disease…
View article: <scp>I</scp>ncreased basal ganglia binding of <sup>18</sup><scp>F‐AV‐1451</scp> in patients with progressive supranuclear palsy
<span>I</span>ncreased basal ganglia binding of <sup>18</sup><span>F‐AV‐1451</span> in patients with progressive supranuclear palsy Open
Background Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work‐up of PSP. Methods Regional tau accumulation was studied using 18 F‐AV‐1451 PET in …